Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.
Identifieur interne : 001206 ( Ncbi/Merge ); précédent : 001205; suivant : 001207Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.
Auteurs : Yunshan Wang [République populaire de Chine] ; Shanhui Sun ; Hong Shen ; Lihua Jiang ; Maoxiu Zhang ; Dongjie Xiao ; Yang Liu ; Xiaoli Ma ; Yong Zhang ; Nongjian Guo ; Tanghong JiaSource :
- Cellular & molecular immunology [ 1672-7681 ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux, Antigènes viraux (immunologie), Autoanticorps (immunologie), Autoanticorps (sang), Faux positifs, Humains, Lignée cellulaire, Maladies auto-immunes (immunologie), Maladies auto-immunes (sang), Réactions croisées, Spécificité des anticorps, Test ELISA, Tests sérologiques, Virus du SRAS (immunologie).
- MESH :
English descriptors
- KwdEn :
- Animals, Antibody Specificity, Antigens, Viral (immunology), Autoantibodies (blood), Autoantibodies (immunology), Autoimmune Diseases (blood), Autoimmune Diseases (immunology), Cell Line, Cross Reactions, Enzyme-Linked Immunosorbent Assay, False Positive Reactions, Humans, SARS Virus (immunology), Serologic Tests.
- MESH :
- chemical , blood : Autoantibodies.
- chemical , immunology : Antigens, Viral, Autoantibodies.
- blood : Autoimmune Diseases.
- immunology : Autoimmune Diseases, SARS Virus.
- Animals, Antibody Specificity, Cell Line, Cross Reactions, Enzyme-Linked Immunosorbent Assay, False Positive Reactions, Humans, Serologic Tests.
Abstract
To investigate the significance of the SARS-associated coronavirus (SARS-CoV) antibody, detected by ELISA and indirect immunofluorescence assays (IFA) for the SARS-CoV Vero E6 cell lysates, in non-SARS subjects, 114 serum samples from healthy controls and 104 serum specimens from autoimmune disease patients were collected. The results of ELISA showed that among 114 sera from healthy controls, 4 (3.5%) were positive of SARS-CoV-IgG antibody and 114 (100%) were all negative of SARS-CoV-IgM antibody; the specificity of SARS-CoV-IgG antibody for SARS patients was 96.5%, but the specificity of both SARS-CoV-IgG and -IgM antibodies for SARS patients was 100%. In 58 cases with SLE, positive rates of SARS-CoV-IgG and -IgM antibodies were 32.8% (19/58) and 8.6% (5/58), respectively, in which 11 cases (19%) were positive of both SARS-CoV-IgG and -IgM antibodies; in 10 cases with SS, positive rate of both SARS-CoV-IgG and -IgM antibodies was 10% (1/10); in 16 cases with MCTD, positive rate of SARS-CoV-IgG was 37.5% (6/16), positive rate of both SARS-CoV-IgG and -IgM antibodies was 6.3% (1/16); in 20 cases with RA, one case was positive (5%) of SARS-CoV-IgG. However, of all samples with positive SARS-CoV-IgG and -IgM antibodies for autoimmune diseases and healthy controls, SARS-CoV RNA and antibodies were all negative by RT-PCR and IFA. All sera for negative or positive ELISA results were also negative or positive results using ELISA with Vero E6 cells lysates. These studies showed that SARS-CoV Vero E6 cell lysates for the ELISA to detect SARS-CoV antibodies could lead to the false-positive reactions or cross-reactions of SARS-CoV antibodies in non-SARS diseases and healthy controls, and the false-positive reactions or cross-reactions were related to Vero E6 cell lysates and autoantibodies in non-SARS population.
PubMed: 16225774
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002500
- to stream PubMed, to step Curation: 002500
- to stream PubMed, to step Checkpoint: 002D64
Links to Exploration step
pubmed:16225774Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.</title>
<author><name sortKey="Wang, Yunshan" sort="Wang, Yunshan" uniqKey="Wang Y" first="Yunshan" last="Wang">Yunshan Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan, China. sdjnwys@163.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan</wicri:regionArea>
<wicri:noRegion>Jinan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sun, Shanhui" sort="Sun, Shanhui" uniqKey="Sun S" first="Shanhui" last="Sun">Shanhui Sun</name>
</author>
<author><name sortKey="Shen, Hong" sort="Shen, Hong" uniqKey="Shen H" first="Hong" last="Shen">Hong Shen</name>
</author>
<author><name sortKey="Jiang, Lihua" sort="Jiang, Lihua" uniqKey="Jiang L" first="Lihua" last="Jiang">Lihua Jiang</name>
</author>
<author><name sortKey="Zhang, Maoxiu" sort="Zhang, Maoxiu" uniqKey="Zhang M" first="Maoxiu" last="Zhang">Maoxiu Zhang</name>
</author>
<author><name sortKey="Xiao, Dongjie" sort="Xiao, Dongjie" uniqKey="Xiao D" first="Dongjie" last="Xiao">Dongjie Xiao</name>
</author>
<author><name sortKey="Liu, Yang" sort="Liu, Yang" uniqKey="Liu Y" first="Yang" last="Liu">Yang Liu</name>
</author>
<author><name sortKey="Ma, Xiaoli" sort="Ma, Xiaoli" uniqKey="Ma X" first="Xiaoli" last="Ma">Xiaoli Ma</name>
</author>
<author><name sortKey="Zhang, Yong" sort="Zhang, Yong" uniqKey="Zhang Y" first="Yong" last="Zhang">Yong Zhang</name>
</author>
<author><name sortKey="Guo, Nongjian" sort="Guo, Nongjian" uniqKey="Guo N" first="Nongjian" last="Guo">Nongjian Guo</name>
</author>
<author><name sortKey="Jia, Tanghong" sort="Jia, Tanghong" uniqKey="Jia T" first="Tanghong" last="Jia">Tanghong Jia</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:16225774</idno>
<idno type="pmid">16225774</idno>
<idno type="wicri:Area/PubMed/Corpus">002500</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002500</idno>
<idno type="wicri:Area/PubMed/Curation">002500</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002500</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D64</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002D64</idno>
<idno type="wicri:Area/Ncbi/Merge">001206</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.</title>
<author><name sortKey="Wang, Yunshan" sort="Wang, Yunshan" uniqKey="Wang Y" first="Yunshan" last="Wang">Yunshan Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan, China. sdjnwys@163.com</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan</wicri:regionArea>
<wicri:noRegion>Jinan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sun, Shanhui" sort="Sun, Shanhui" uniqKey="Sun S" first="Shanhui" last="Sun">Shanhui Sun</name>
</author>
<author><name sortKey="Shen, Hong" sort="Shen, Hong" uniqKey="Shen H" first="Hong" last="Shen">Hong Shen</name>
</author>
<author><name sortKey="Jiang, Lihua" sort="Jiang, Lihua" uniqKey="Jiang L" first="Lihua" last="Jiang">Lihua Jiang</name>
</author>
<author><name sortKey="Zhang, Maoxiu" sort="Zhang, Maoxiu" uniqKey="Zhang M" first="Maoxiu" last="Zhang">Maoxiu Zhang</name>
</author>
<author><name sortKey="Xiao, Dongjie" sort="Xiao, Dongjie" uniqKey="Xiao D" first="Dongjie" last="Xiao">Dongjie Xiao</name>
</author>
<author><name sortKey="Liu, Yang" sort="Liu, Yang" uniqKey="Liu Y" first="Yang" last="Liu">Yang Liu</name>
</author>
<author><name sortKey="Ma, Xiaoli" sort="Ma, Xiaoli" uniqKey="Ma X" first="Xiaoli" last="Ma">Xiaoli Ma</name>
</author>
<author><name sortKey="Zhang, Yong" sort="Zhang, Yong" uniqKey="Zhang Y" first="Yong" last="Zhang">Yong Zhang</name>
</author>
<author><name sortKey="Guo, Nongjian" sort="Guo, Nongjian" uniqKey="Guo N" first="Nongjian" last="Guo">Nongjian Guo</name>
</author>
<author><name sortKey="Jia, Tanghong" sort="Jia, Tanghong" uniqKey="Jia T" first="Tanghong" last="Jia">Tanghong Jia</name>
</author>
</analytic>
<series><title level="j">Cellular & molecular immunology</title>
<idno type="ISSN">1672-7681</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibody Specificity</term>
<term>Antigens, Viral (immunology)</term>
<term>Autoantibodies (blood)</term>
<term>Autoantibodies (immunology)</term>
<term>Autoimmune Diseases (blood)</term>
<term>Autoimmune Diseases (immunology)</term>
<term>Cell Line</term>
<term>Cross Reactions</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>False Positive Reactions</term>
<term>Humans</term>
<term>SARS Virus (immunology)</term>
<term>Serologic Tests</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antigènes viraux (immunologie)</term>
<term>Autoanticorps (immunologie)</term>
<term>Autoanticorps (sang)</term>
<term>Faux positifs</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Maladies auto-immunes (immunologie)</term>
<term>Maladies auto-immunes (sang)</term>
<term>Réactions croisées</term>
<term>Spécificité des anticorps</term>
<term>Test ELISA</term>
<term>Tests sérologiques</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Autoantibodies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term>
<term>Autoantibodies</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Autoimmune Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term>
<term>Autoanticorps</term>
<term>Maladies auto-immunes</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Autoimmune Diseases</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Autoanticorps</term>
<term>Maladies auto-immunes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Antibody Specificity</term>
<term>Cell Line</term>
<term>Cross Reactions</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>False Positive Reactions</term>
<term>Humans</term>
<term>Serologic Tests</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Faux positifs</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Réactions croisées</term>
<term>Spécificité des anticorps</term>
<term>Test ELISA</term>
<term>Tests sérologiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To investigate the significance of the SARS-associated coronavirus (SARS-CoV) antibody, detected by ELISA and indirect immunofluorescence assays (IFA) for the SARS-CoV Vero E6 cell lysates, in non-SARS subjects, 114 serum samples from healthy controls and 104 serum specimens from autoimmune disease patients were collected. The results of ELISA showed that among 114 sera from healthy controls, 4 (3.5%) were positive of SARS-CoV-IgG antibody and 114 (100%) were all negative of SARS-CoV-IgM antibody; the specificity of SARS-CoV-IgG antibody for SARS patients was 96.5%, but the specificity of both SARS-CoV-IgG and -IgM antibodies for SARS patients was 100%. In 58 cases with SLE, positive rates of SARS-CoV-IgG and -IgM antibodies were 32.8% (19/58) and 8.6% (5/58), respectively, in which 11 cases (19%) were positive of both SARS-CoV-IgG and -IgM antibodies; in 10 cases with SS, positive rate of both SARS-CoV-IgG and -IgM antibodies was 10% (1/10); in 16 cases with MCTD, positive rate of SARS-CoV-IgG was 37.5% (6/16), positive rate of both SARS-CoV-IgG and -IgM antibodies was 6.3% (1/16); in 20 cases with RA, one case was positive (5%) of SARS-CoV-IgG. However, of all samples with positive SARS-CoV-IgG and -IgM antibodies for autoimmune diseases and healthy controls, SARS-CoV RNA and antibodies were all negative by RT-PCR and IFA. All sera for negative or positive ELISA results were also negative or positive results using ELISA with Vero E6 cells lysates. These studies showed that SARS-CoV Vero E6 cell lysates for the ELISA to detect SARS-CoV antibodies could lead to the false-positive reactions or cross-reactions of SARS-CoV antibodies in non-SARS diseases and healthy controls, and the false-positive reactions or cross-reactions were related to Vero E6 cell lysates and autoantibodies in non-SARS population.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16225774</PMID>
<DateCompleted><Year>2006</Year>
<Month>02</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2005</Year>
<Month>10</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1672-7681</ISSN>
<JournalIssue CitedMedium="Print"><Volume>1</Volume>
<Issue>4</Issue>
<PubDate><Year>2004</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Cellular & molecular immunology</Title>
<ISOAbbreviation>Cell. Mol. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases.</ArticleTitle>
<Pagination><MedlinePgn>304-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText>To investigate the significance of the SARS-associated coronavirus (SARS-CoV) antibody, detected by ELISA and indirect immunofluorescence assays (IFA) for the SARS-CoV Vero E6 cell lysates, in non-SARS subjects, 114 serum samples from healthy controls and 104 serum specimens from autoimmune disease patients were collected. The results of ELISA showed that among 114 sera from healthy controls, 4 (3.5%) were positive of SARS-CoV-IgG antibody and 114 (100%) were all negative of SARS-CoV-IgM antibody; the specificity of SARS-CoV-IgG antibody for SARS patients was 96.5%, but the specificity of both SARS-CoV-IgG and -IgM antibodies for SARS patients was 100%. In 58 cases with SLE, positive rates of SARS-CoV-IgG and -IgM antibodies were 32.8% (19/58) and 8.6% (5/58), respectively, in which 11 cases (19%) were positive of both SARS-CoV-IgG and -IgM antibodies; in 10 cases with SS, positive rate of both SARS-CoV-IgG and -IgM antibodies was 10% (1/10); in 16 cases with MCTD, positive rate of SARS-CoV-IgG was 37.5% (6/16), positive rate of both SARS-CoV-IgG and -IgM antibodies was 6.3% (1/16); in 20 cases with RA, one case was positive (5%) of SARS-CoV-IgG. However, of all samples with positive SARS-CoV-IgG and -IgM antibodies for autoimmune diseases and healthy controls, SARS-CoV RNA and antibodies were all negative by RT-PCR and IFA. All sera for negative or positive ELISA results were also negative or positive results using ELISA with Vero E6 cells lysates. These studies showed that SARS-CoV Vero E6 cell lysates for the ELISA to detect SARS-CoV antibodies could lead to the false-positive reactions or cross-reactions of SARS-CoV antibodies in non-SARS diseases and healthy controls, and the false-positive reactions or cross-reactions were related to Vero E6 cell lysates and autoantibodies in non-SARS population.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yunshan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Central Laboratory, Jinan Central Hospital, Clinical Medical College of Shandong University, Jinan, China. sdjnwys@163.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sun</LastName>
<ForeName>Shanhui</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shen</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jiang</LastName>
<ForeName>Lihua</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Maoxiu</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xiao</LastName>
<ForeName>Dongjie</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ma</LastName>
<ForeName>Xiaoli</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Guo</LastName>
<ForeName>Nongjian</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jia</LastName>
<ForeName>Tanghong</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Cell Mol Immunol</MedlineTA>
<NlmUniqueID>101242872</NlmUniqueID>
<ISSNLinking>1672-7681</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005189" MajorTopicYN="N">False Positive Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012698" MajorTopicYN="N">Serologic Tests</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>10</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>10</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16225774</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><noCountry><name sortKey="Guo, Nongjian" sort="Guo, Nongjian" uniqKey="Guo N" first="Nongjian" last="Guo">Nongjian Guo</name>
<name sortKey="Jia, Tanghong" sort="Jia, Tanghong" uniqKey="Jia T" first="Tanghong" last="Jia">Tanghong Jia</name>
<name sortKey="Jiang, Lihua" sort="Jiang, Lihua" uniqKey="Jiang L" first="Lihua" last="Jiang">Lihua Jiang</name>
<name sortKey="Liu, Yang" sort="Liu, Yang" uniqKey="Liu Y" first="Yang" last="Liu">Yang Liu</name>
<name sortKey="Ma, Xiaoli" sort="Ma, Xiaoli" uniqKey="Ma X" first="Xiaoli" last="Ma">Xiaoli Ma</name>
<name sortKey="Shen, Hong" sort="Shen, Hong" uniqKey="Shen H" first="Hong" last="Shen">Hong Shen</name>
<name sortKey="Sun, Shanhui" sort="Sun, Shanhui" uniqKey="Sun S" first="Shanhui" last="Sun">Shanhui Sun</name>
<name sortKey="Xiao, Dongjie" sort="Xiao, Dongjie" uniqKey="Xiao D" first="Dongjie" last="Xiao">Dongjie Xiao</name>
<name sortKey="Zhang, Maoxiu" sort="Zhang, Maoxiu" uniqKey="Zhang M" first="Maoxiu" last="Zhang">Maoxiu Zhang</name>
<name sortKey="Zhang, Yong" sort="Zhang, Yong" uniqKey="Zhang Y" first="Yong" last="Zhang">Yong Zhang</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Wang, Yunshan" sort="Wang, Yunshan" uniqKey="Wang Y" first="Yunshan" last="Wang">Yunshan Wang</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001206 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001206 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:16225774 |texte= Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16225774" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |